Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Lower-Extremity Kinetic Chain Exercise Program for Achilles Tendinopathy

NCT07730866 · tracked via the Priya Life Science Egypt tracker
Sponsor
May University in Cairo
Phase
Not applicable
Started
2026-06-06
Last updated
2026-07-28

Condition(s) studied

Achilles Tendinopathy (AT)

Investigational drug(s) / intervention(s)

Lower-Extremity Kinetic Chain Exercise ProgramConventional Exercise Program

Lower-Extremity Kinetic Chain Exercise Program: The program includes progressive exercises targeting the foot, ankle, knee, hip, and trunk while addressing movement patterns throughout the lower-extremity kinetic chain

Conventional Exercise Program: A standard rehabilitation program consisting of conventional therapeutic exercises commonly prescribed for chronic Achilles tendinopathy, including tendon-loading and lowe

Study summary

Achilles tendinopathy is a common condition that causes pain, stiffness, and reduced function of the Achilles tendon. It can affect both physically active individuals and the general adult population, often making everyday activities and exercise more difficult. Exercise therapy is widely used as the primary conservative treatment; however, rehabilitation programs that focus only on the Achilles tendon may not address movement impairments involving the entire lower extremity.

This randomized controlled trial will evaluate a rehabilitation program based on the lower-extremity kinetic chain in adults with chronic mid-portion Achilles tendinopathy. Fifty participants will be randomly assigned to receive either a kinetic chain-based exercise program or a conventional rehabilitation program. Assessments will be completed before the intervention begins and again after it is finished.

The study will measure postural stability using the Biodex Balance System, foot and ankle function using the Foot and Ankle Outcome Score (FAOS), pain intensity using the Visual Analog Scale (VAS), and ankle range of motion using a goniometer.

The results will provide information on the effects of a rehabilitation approach that addresses the coordinated function of the lower extremity in people with chronic Achilles tendinopathy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: \- Adults aged 18-45 years. * Male and female participants. * Clinical diagnosis of Achilles tendinopathy, confirmed by an orthopedic physician or physiotherapist and history of Achilles tendon surgery or lower-limb surgery within the previous 12 months. * Symptoms (pain, stiffness, and impaired function) persisting for at least 3 months (chronic Achilles tendinopathy). * Pain reproduced during tendon-loading activities (e.g., walking, running, hopping, or single-leg heel raises). * Ability to walk independently without an assistive device. * Body Mass Index (BMI) between 18.5 and \<30 kg/m². * Willingness to participate and provide written informed consent. Exclusion Criteria: \- Patients with insertional Achilles tendinopathy or a partial/complete Achilles tendon rupture. History of lower-limb fracture within the previous 12 months. * Presence of systemic inflammatory, rheumatologic, or connective tissue disorders (e.g., rheumatoid arthritis, ankylosing spondylitis). * Neurological disorders affecting balance, gait, or lower-limb function (e.g., stroke, Parkinson's disease, peripheral neuropathy, multiple sclerosis). * Vestibular disorders or other conditions known to impair postural stability.

Primary outcome measure(s)

  • overall stability index — Baseline and immediately after completion of the 8-week intervention
    The Overall Stability Index (OSI) will be measured using the Biodex Balance System to assess dynamic postural stability. The OSI quantifies the variance of platform displacement from level in all directions during dynamic balance testing. Lower OSI values indicate better postural stability, whereas higher values indicate greater postural instability.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Physical Therapy, May University in Cairo Cairo Cairo Governorate

More May University in Cairo trials in Egypt

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07730866 on ClinicalTrials.gov ↗ ← All trials in Egypt